Literature DB >> 6319484

A cephalosporin active in vivo against Nocardia: efficacy of cefotaxime in murine model of acute pulmonary nocardiosis.

A M Sugar, R S Chahal, D A Stevens.   

Abstract

Cefotaxime, a cephalosporin drug, has been shown to be active in vitro against nocardiae, a finding confirmed in this study. Pharmacokinetic studies were performed in mice to define regimens which provided peak serum levels comparable to that achieved in man with currently used doses. These regimens were shown to be effective with only short courses of therapy of rapidly progressive and highly lethal N. asteroides infection, produced by pulmonary challenge of mice. This suggests the possible utility of this drug in human nocardiosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6319484      PMCID: PMC2129341          DOI: 10.1017/s0022172400060459

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  23 in total

1.  Treatment of a cutaneous Nocardia asteroides infection with minocycline hydrochloride.

Authors:  E Epstein
Journal:  West J Med       Date:  1974-06

2.  Activity of minocycline against Nocardia asteroides: comparison with tetracycline in agar-dilution and standard disc-diffusion tests and with sulfadiazine in an experimental infection of mice.

Authors:  M C Bach; O Gold; M Finland
Journal:  J Lab Clin Med       Date:  1973-05

3.  Treatment of nocardial infection with trimethoprim and sulfamethoxazole.

Authors:  E G Maderazo; R Quintiliani
Journal:  Am J Med       Date:  1974-10       Impact factor: 4.965

4.  Nocardia asteroides infection complicating neoplastic disease.

Authors:  L S Young; D Armstrong; A Blevins; P Lieberman
Journal:  Am J Med       Date:  1971-03       Impact factor: 4.965

5.  Structural and biochemical alterations of Nocardia asteroides cell walls during its growth cycle.

Authors:  B L Beaman
Journal:  J Bacteriol       Date:  1975-09       Impact factor: 3.490

6.  Disk diffusion susceptibility testing of Nocardia species.

Authors:  R J Wallace; E J Septimus; D M Musher; R R Martin
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

7.  A method for determining in-vitro drug susceptibilities of some Nocardiae and Actinomadurae: results with 17 antimicrobial agents.

Authors:  G F Carroll; J M Brown; L D Haley
Journal:  Am J Clin Pathol       Date:  1977-08       Impact factor: 2.493

8.  Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

Authors:  J N Galgiani; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

9.  Susceptibility of Nocardia asteroides to 45 antimicrobial agents in vitro.

Authors:  M C Bach; L D Sabath; M Finland
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

10.  Synergistic action of ampicillin and erythromycin against Nocardia asteroides: effect of time of incubation.

Authors:  M Finland; M C Bach; C Garner; O Gold
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

View more
  4 in total

1.  Biochemical-genetic analysis and distribution of FAR-1, a class A beta-lactamase from Nocardia farcinica.

Authors:  F Laurent; L Poirel; T Naas; E B Chaibi; R Labia; P Boiron; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 3.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

4.  Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31.

Authors:  Venkata Raveendra Pothineni; Hari-Hara S K Potula; Aditya Ambati; Venkata Vamsee Aditya Mallajosyula; Brindha Sridharan; Mohammed Inayathullah; Mohamed Sohail Ahmed; Jayakumar Rajadas
Journal:  Sci Rep       Date:  2020-03-02       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.